Becton, Dickinson and Company (BDX)

Market Cap	53.76B
Revenue (ttm)	21.39B
Net Income (ttm)	1.59B
Shares Out	286.63M
EPS (ttm)	5.47
PE Ratio	34.29
Forward PE	12.96
Dividend	$4.16 (2.22%)
Ex-Dividend Date	Sep 8, 2025

Volume	1,060,089
Open	186.81
Previous Close	186.21
Day's Range	186.72 - 190.02
52-Week Range	163.33 - 251.99
Beta	0.30
Analysts	Buy
Price Target	222.75 (+18.76%)
Earnings Date	Nov 6, 2025

About BDX

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: Apr 23, 1962
• Employees: 74,000
• Stock Exchange: NYSE
• Ticker Symbol: BDX
• Website: https://www.bd.com

Financial Performance

In 2024, BDX's revenue was $20.18 billion, an increase of 4.16% compared to the previous year's $19.37 billion. Earnings were $1.71 billion, an increase of 19.73%.

Analyst Summary

According to 9 analysts, the average rating for BDX stock is "Buy." The 12-month stock price target is $222.75, which is an increase of 18.76% from the latest price.

Price Target

$222.75

(18.76% upside)

Analyst Consensus: Buy